Effetto Cardioprotettivo della Melatonina Versus la Vitamina D nei Pazienti con Cancro al Seno che Ricevono Doxorubicina
Studio Clinico Valutante l'Effetto Cardioprotettivo della Melatonina Versus la Vitamina D in Pazienti con Cancro al Seno Sottoposte a Doxorubicina
This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Doxorubicin is one of the most potent chemotherapeutic agents and is widely used for the treatment of various cancers and hematological malignancies . Although Doxorubicin has a potential beneficial effect in cancer treatment, its dose-dependent cardio toxicity is considered a major challenge.
Doxorubicin is known to generate free radicals either by redox cycling between a semiquinone form and a quinone form or by forming a Doxorubicin-Fe3+ complex . In both pathways, molecular oxygen is reduced to superoxide ion , which is converted to other forms of reactive oxygen species such as hydrogen peroxide and hydroxyl radical . These free radicals could then cause membrane and macromolecule damage, both of which lead to injury to the heart, an organ that has a relatively low level of antioxidant enzymes such as superoxide dismutase and catalase .
Furthermore, it was revealed that Doxorubicin may enhance the death of cardiomyocytes by affecting the tumor necrosis factor signaling pathway via increasing the expression and levels of inflammatory genes interleukin and interleukin -6 .
To alleviate DOX-induced toxicity, researchers have tested a number of strategies, including the administration of antioxidants and/or antiapoptotic agents, in both in vitro and in vivo models of Doxorubicin induced cytotoxicity, but most of these trials have failed to translate into clinical benefits . As a result, there are no effective approaches for alleviating Doxorubicin induced cytotoxicity despite intensive research over recent decades .
Melatonin is a natural hormone that is primarily secreted by the pineal gland and functions as a major regulator of circadian rhythms in humans . Melatonin also plays a variety of biological roles as a modulator of mood, sexual behavior and sleep; low levels or a deficiency of melatonin are also associated with Parkinson's disease, Alzheimer's disease, epilepsy, ischemic injury, diabetes, and even cancer .
Melatonin has emerged as a promising adjuvant that protects against doxorubicin-induced cytotoxicity, as highlighted by various studies and clinical trials that have demonstrated cardioprotective effects against several chemotherapeutic agents . Moreover, melatonin exhibits low toxicity and easily enters cells owing to its good solubility in both aqueous and organic phases and its highly lipophilic properties . Vitamin D plays an important role in the regulation of body function including the cardiovascular system .
Vitamin D deficiency results in the decrease of active calcitriol leading to inhibition of proliferation of cardiomyocytes and vascular smooth muscles .
This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Tanta, Egitto
- Tanta University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age from 18 to 65 years old.
- Gender: female.
- Positive breast cancer women who are scheduled to receive Doxorubicin.
- Have a good performance status according to the eastern cooperative oncology group with a score of 0-2.
- Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%.
- Normal renal and liver function tests.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Women with HER-2 positive of breast cancer.
- Formerly treated with Doxorubicin.
- Patients with a known hypersensitivity to any of the used drugs.
- On other concomitant vitamins or food supplements.
- Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.
- Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction < 50%.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Group 1 (Doxorubicin group)
30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks. |
30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks. |
|
Sperimentale: Group 2 (Vitamin D group)
patients with Vitamin D supplementation (1000 iu/day) plus Doxorubicin for 12 weeks |
patients with Vitamin D supplementation (1000 iu/day) plus traditional therapy for 12 weeks |
|
Sperimentale: Group 3 (melatonin group)
30 patients with 10 mg of melatonin orally, once daily plus Doxorubicin for 12 weeks. |
patients with 10 mg of melatonin orally, once daily plus traditional therapy for 12 weeks |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Decreasing incidence and severity of cardiotoxicity
Lasso di tempo: 12 weeks
|
Assessment of decreasing incidence and severity of cardiotoxicity by echocardiogram and ejection fraction is associated with doxorubicin treatment. |
12 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Plasma B-Type Natriuretic Peptide (BNP) Concentration
Lasso di tempo: Baseline and 12 weeks.
|
Change in plasma B-type natriuretic peptide (BNP) concentration from baseline to 12 weeks, measured using a chemiluminescent microparticle immunoassay (CMIA) on the Abbott Alinity i analyzer. Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in pg/mL. |
Baseline and 12 weeks.
|
|
Change in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentration
Lasso di tempo: Baseline and 12 weeks.
|
Change in serum/plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline to 12 weeks, measured using a chemiluminescent microparticle immunoassay (CMIA) on the Abbott Alinity i analyzer. Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in pg/mL. |
Baseline and 12 weeks.
|
|
Change in High-Sensitivity Cardiac Troponin I (hs-cTnI) Concentration
Lasso di tempo: Baseline and 12 weeks.
|
Change in serum/plasma high-sensitivity cardiac troponin I (hs-cTnI) concentration from baseline to 12 weeks, measured using the Alinity i STAT High Sensitive Troponin-I chemiluminescent microparticle immunoassay (CMIA). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/L. |
Baseline and 12 weeks.
|
|
Change in Myeloperoxidase (MPO) Concentration
Lasso di tempo: Baseline and 12 weeks.
|
Change in myeloperoxidase (MPO) concentration from baseline to 12 weeks, measured using a human MPO double-antibody sandwich enzyme-linked immunosorbent assay (ELISA; SunRed Biological Technology Co., Ltd.). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/mL. |
Baseline and 12 weeks.
|
|
Change in Interleukin-6 (IL-6) Concentration
Lasso di tempo: Baseline and 12 weeks.
|
Change in interleukin-6 (IL-6) concentration from baseline to 12 weeks, measured using a human IL-6 double-antibody sandwich enzyme-linked immunosorbent assay (ELISA; SunRed Biological Technology Co., Ltd.). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/L. |
Baseline and 12 weeks.
|
|
Change in Creatine Kinase-MB (CK-MB) Concentration
Lasso di tempo: Baseline and 12 weeks.
|
Change in serum/plasma creatine kinase-MB (CK-MB) concentration from baseline to 12 weeks, measured using the Alinity i STAT CK-MB chemiluminescent microparticle immunoassay (CMIA). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/mL. |
Baseline and 12 weeks.
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 36265MD408/5/25
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
All data will be available when needed
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- ICF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .